Bactericidal efficacy of mupirocin in multi-antibiotic resistant Staphylococcus aureus burn wound infection

Methicillin resistant Staphylococcus aureus strains (MRSA) have become increasingly prevalent as pathogenic organisms, especially in burn wounds, with an associated mortality of 20-40% among those clinically infected. Mupirocin ointment, a new topical antibiotic, has proved in vitro and in vivo to b...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1988-05, Vol.21 (5), p.589-595
Main Authors: RODE, H, DE WET, P. M, MILLAR, A. J. W, CYWES, S
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Biological Availability
Burns - complications
Burns - drug therapy
Drug Resistance, Microbial
Fatty Acids - administration & dosage
Fatty Acids - pharmacokinetics
Fatty Acids - pharmacology
Medical sciences
Mupirocin
Ointments
Pharmacology. Drug treatments
Rats
Staphylococcal Skin Infections - drug therapy
Staphylococcus aureus - drug effects
Wound Infection - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methicillin resistant Staphylococcus aureus strains (MRSA) have become increasingly prevalent as pathogenic organisms, especially in burn wounds, with an associated mortality of 20-40% among those clinically infected. Mupirocin ointment, a new topical antibiotic, has proved in vitro and in vivo to be highly effective in the treatment of MRSA infections. A modified Walker burn wound model was used to define the rate of trans-eschar penetration, biodynamic availability and bactericidal efficacy of 2% mupirocin ointment in established MRSA burn wound infection. In-vitro penetration trials confirmed the effective diffusion of mupirocin through 1.5 mm eschar within 2 h. A single topical application of mupirocin resulted in a 98.3% (5.67 x 10(8) cfu/g of tissue--1.0 x 10(7) cfu/g of tissue) reduction in intra-eschar viable organisms within 36 h post application. A second topical application of mupirocin at 24 h resulted in a total reduction of 99.6% in viable intra-eschar organisms (1.85 x 10(8) cfu/gram of tissue--6.76 x 10(5) cfu/g of tissue). It is concluded that mupirocin is highly effective in controlling MRSA burn wound infection and should be applied topically every 24 h.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/21.5.589